HC Wainwright Reaffirms “Buy” Rating for Kura Oncology (NASDAQ:KURA)

HC Wainwright reissued their buy rating on shares of Kura Oncology (NASDAQ:KURA) in a research report sent to investors on Friday, Benzinga reports. They currently have a $32.00 price objective on the stock.

KURA has been the topic of several other research reports. Wedbush reissued an outperform rating and set a $37.00 target price on shares of Kura Oncology in a research report on Friday. JMP Securities boosted their price objective on shares of Kura Oncology from $22.00 to $32.00 and gave the company a market outperform rating in a report on Wednesday, January 31st. Finally, StockNews.com lowered Kura Oncology from a hold rating to a sell rating in a research note on Monday, April 15th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and seven have issued a buy rating to the stock. According to MarketBeat.com, Kura Oncology currently has an average rating of Moderate Buy and a consensus price target of $28.28.

Kura Oncology Stock Up 0.2 %

KURA stock traded up $0.04 during trading on Friday, hitting $20.63. 605,625 shares of the company’s stock traded hands, compared to its average volume of 831,868. The business has a fifty day simple moving average of $20.66 and a two-hundred day simple moving average of $15.94. The company has a quick ratio of 12.26, a current ratio of 12.26 and a debt-to-equity ratio of 0.02. The firm has a market capitalization of $1.57 billion, a P/E ratio of -9.51 and a beta of 0.89. Kura Oncology has a 1 year low of $7.41 and a 1 year high of $24.17.

Kura Oncology (NASDAQ:KURA) last announced its earnings results on Thursday, May 2nd. The company reported ($0.59) earnings per share for the quarter, missing the consensus estimate of ($0.56) by ($0.03). During the same period in the previous year, the firm posted ($0.50) earnings per share. The firm’s revenue for the quarter was up .0% on a year-over-year basis. Sell-side analysts anticipate that Kura Oncology will post -2.35 EPS for the current year.

Hedge Funds Weigh In On Kura Oncology

A number of institutional investors have recently modified their holdings of the stock. Signaturefd LLC grew its holdings in Kura Oncology by 40.4% during the fourth quarter. Signaturefd LLC now owns 5,038 shares of the company’s stock worth $72,000 after acquiring an additional 1,449 shares during the period. China Universal Asset Management Co. Ltd. grew its stake in shares of Kura Oncology by 352.6% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 8,590 shares of the company’s stock worth $124,000 after purchasing an additional 6,692 shares during the period. Saxon Interests Inc. acquired a new stake in shares of Kura Oncology during the 1st quarter worth approximately $201,000. Pale Fire Capital SE purchased a new position in shares of Kura Oncology during the 3rd quarter valued at approximately $92,000. Finally, E Fund Management Co. Ltd. lifted its stake in shares of Kura Oncology by 12.2% in the 3rd quarter. E Fund Management Co. Ltd. now owns 11,929 shares of the company’s stock valued at $109,000 after purchasing an additional 1,301 shares during the period.

About Kura Oncology

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.